31st Jul 2013 07:00
For immediate release | 31 July 2013 |
ABCAM PLC
("Abcam" or the "Company")
Notification of Full Year Results
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, will announce its preliminary results for the year ended 30 June 2013 on Tuesday 10 September 2013.
A briefing for analysts will be held at 10.30am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
For further information:
Abcam | + 44 (0) 1223 696 000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer | |
www.abcam.com | |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield - Nominated Adviser | |
James Black - Corporate Broking | |
Peel Hunt LLP - Joint Broker | + 44 (0) 207 418 8900 |
Andy Crossley - Corporate Broking | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles | |
Notes to editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 122,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships to over 130 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com
Related Shares:
ABC.L